GB202012161D0 - Combination therapy - Google Patents
Combination therapyInfo
- Publication number
- GB202012161D0 GB202012161D0 GBGB2012161.2A GB202012161A GB202012161D0 GB 202012161 D0 GB202012161 D0 GB 202012161D0 GB 202012161 A GB202012161 A GB 202012161A GB 202012161 D0 GB202012161 D0 GB 202012161D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- combination therapy
- therapy
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2012161.2A GB202012161D0 (en) | 2020-08-05 | 2020-08-05 | Combination therapy |
| PCT/EP2021/071861 WO2022029223A1 (en) | 2020-08-05 | 2021-08-05 | Combination therapy comprising anti-kaag1 antibody drug conjugate and parp inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2012161.2A GB202012161D0 (en) | 2020-08-05 | 2020-08-05 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202012161D0 true GB202012161D0 (en) | 2020-09-16 |
Family
ID=72425127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2012161.2A Ceased GB202012161D0 (en) | 2020-08-05 | 2020-08-05 | Combination therapy |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202012161D0 (en) |
| WO (1) | WO2022029223A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SI1934174T1 (en) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| JP5503706B2 (en) | 2012-08-14 | 2014-05-28 | 株式会社サンフロイント | Poultice applicator |
| UA123889C2 (en) * | 2017-02-08 | 2021-06-16 | Ейдісі Терапьютікс Са | PYROLOBENZODIAZEPINE-ANTIBODY CONJUGATES |
-
2020
- 2020-08-05 GB GBGB2012161.2A patent/GB202012161D0/en not_active Ceased
-
2021
- 2021-08-05 WO PCT/EP2021/071861 patent/WO2022029223A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022029223A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304223A (en) | Combination therapy | |
| IL319599A (en) | Combination therapy | |
| GB202103164D0 (en) | Therapy | |
| GB202004189D0 (en) | Combination therapy | |
| GB202002639D0 (en) | Therapy | |
| IL318268A (en) | Combination therapy | |
| GB202111288D0 (en) | Combination therapy | |
| GB202104037D0 (en) | Combination therapy | |
| GB202111035D0 (en) | Therapy | |
| GB202108303D0 (en) | Therapy | |
| GB202109375D0 (en) | Combination therapy | |
| GB202109377D0 (en) | Combination therapy | |
| GB202109373D0 (en) | Combination therapy | |
| GB202107824D0 (en) | Combination therapy | |
| GB202107713D0 (en) | Combination therapy | |
| GB202107706D0 (en) | Combination therapy | |
| GB202107709D0 (en) | Combination therapy | |
| GB202015916D0 (en) | Combination therapy | |
| GB202012161D0 (en) | Combination therapy | |
| GB202009178D0 (en) | Combination therapy | |
| GB202117706D0 (en) | Therapy | |
| GB202109893D0 (en) | PeptiBAC therapy | |
| GB202104427D0 (en) | Therapy | |
| GB202102211D0 (en) | PeptiBAC therapy | |
| GB202019218D0 (en) | Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |